Cargando…
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients
PURPOSE: Intrahepatic cholangiocarcinoma (IHCCA), a global health problem, is increasing in incidence and has differing etiologies worldwide. Next-generation sequencing (NGS) is rapidly being incorporated into the clinical management of biliary cancers. IHCCA is enriched with actionable mutations, a...
Autores principales: | Cao, Jingyu, Hu, Jing, Liu, Siqin, Meric-Bernstam, Funda, Abdel-Wahab, Reham, Xu, Junjie, Li, Qiang, Yan, Maolin, Feng, Yujie, Lin, Jianzhen, Zhao, Songhui, Wang, Jian, Kwong, Lawrence N., Hu, Jinwei, Carapeto, Fernando, Borad, Mitesh J., Wang, Kai, Javle, Milind, Zhao, Haitao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446410/ https://www.ncbi.nlm.nih.gov/pubmed/32923885 http://dx.doi.org/10.1200/PO.18.00414 |
Ejemplares similares
-
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer
por: Abdel-Wahab, Reham, et al.
Publicado: (2020) -
Systemic and Adjuvant Therapies for Intrahepatic
Cholangiocarcinoma
por: Chun, Yun Shin, et al.
Publicado: (2017) -
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
por: DiPeri, Timothy P., et al.
Publicado: (2022) -
Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers
por: Connor, Ashton A., et al.
Publicado: (2022) -
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)